ADMA Biologics, Inc. (ADMA) — ESG & Values Scores

Environment story

ADMA Biologics operates as a biopharmaceutical manufacturer with limited direct environmental disclosure in filings. No Scope 1, Scope 2, or Scope 3 emissions data, net-zero targets, renewable energy percentages, or climate-related initiatives are disclosed in provided documents. The company acknowledges environmental compliance obligations under hazardous-waste and lab-procedure regulations, but presents no affirmative decarbonization strategy, green infrastructure investments, or environmental commitments. Risk factors describe potential contamination and cleanup liabilities from biological and hazardous materials handling. No climate transition plan, carbon reduction targets, or environmental sustainability reporting detected.

Criticisms on file

Potential contamination and cleanup liabilities from biological and hazardous waste materials
Source: ADMA_10k.txt, Risk Factors section: 'If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.'

Disclosed initiatives

Environmental, Health & Safety Compliance

Company acknowledges compliance with environmental laws governing laboratory procedures, hazardous materials handling, storage, treatment, and disposal. Contracts with third parties for hazardous waste disposal.

Operational risk mitigation; no affirmative decarbonization benefit.

Social story

ADMA Biologics discloses minimal social metrics in provided filings. No CEO-to-median-worker pay ratio, workforce diversity percentages (women, underrepresented groups), turnover rates, or formal union-standing disclosures are provided. Management composition is referenced only by naming executive officers (e.g., Adam S. Grossman, President and CEO); no breakdown of board independence, gender, or racial diversity is detailed. The company identifies reliance on third-party plasma donors and plasma collection facilities, but no supply-chain labor audits, human-rights policies, or living-wage commitments are disclosed. Risk factors acknowledge employee retention challenges and competitive talent recruitment but do not address diversity initiatives, pay equity, or labor relations.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Employee Hiring and Retention

Company acknowledges need to hire qualified personnel across R&D, manufacturing, sales, regulatory affairs, and finance. Notes competition for talent and acknowledges importance of personnel retention.

Internal capability building; no documented diversity or equity program.
Plasma Donor and Center Operations

ADMA BioCenters operates eight FDA-licensed plasma collection facilities. Manages donor recruitment, screening, and plasma collection processes.

Source material control; no disclosed labor auditing or donor-welfare protocols beyond FDA compliance.

Governance story

ADMA Biologics filings provide limited governance transparency. No board independence percentage, share-class structure, lobbying expenditure, PAC contributions, or governance committee composition are disclosed in provided documents. The company references employment agreements with executive officers and identifies Adam S. Grossman as President and CEO but offers no detail on board structure, committee oversight, or compensation policies. Risk factors mention reliance on key management and absence of key-person insurance but do not address dual-class voting, board diversity, or governance controversies. Debt covenants under JPMorgan Credit Agreement include financial and operational restrictions, indicating lender-imposed governance constraints. No antitrust proceedings, securities fraud allegations, privacy fines, or SEC consent decrees are evident in provided text.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

JPMorgan Credit Agreement Covenants

August 5, 2025 senior secured credit facility with $300M total commitment includes maximum total leverage ratio of 2.50:1.00 and minimum fixed charge coverage ratio of 1.20:1.00. Negative covenants restrict indebtedness, asset sales, and affiliate transactions.

External lender-imposed financial and operational discipline.
Regulatory Compliance and FDA Inspections

Company subject to periodic FDA and state inspections of manufacturing and plasma collection facilities. Risk factors acknowledge regulatory scrutiny and potential enforcement actions.

Regulatory oversight; no affirmative governance innovation detected.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of ADMA Biologics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open ADMA Biologics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)